Compare STVN & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STVN | ALKS |
|---|---|---|
| Founded | 1949 | 1987 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 5.7B |
| IPO Year | N/A | N/A |
| Metric | STVN | ALKS |
|---|---|---|
| Price | $15.88 | $33.01 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 13 |
| Target Price | $23.75 | ★ $42.85 |
| AVG Volume (30 Days) | 1.0M | ★ 2.0M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 0.40% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.42 | N/A |
| Revenue Next Year | $9.61 | $23.22 |
| P/E Ratio | $26.70 | ★ $16.31 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.91 | $25.17 |
| 52 Week High | $28.00 | $36.45 |
| Indicator | STVN | ALKS |
|---|---|---|
| Relative Strength Index (RSI) | 40.83 | 50.93 |
| Support Level | $15.43 | $33.04 |
| Resistance Level | $16.69 | $34.27 |
| Average True Range (ATR) | 0.99 | 1.09 |
| MACD | 0.19 | -0.30 |
| Stochastic Oscillator | 60.60 | 16.61 |
Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.